Madrigal Pharmaceuticals Stock Today

MDGL Stock  USD 285.86  4.46  1.54%   

Performance

8 of 100

 
Weak
 
Strong
OK

Odds Of Distress

Less than 8

 
High
 
Low
Low
Madrigal Pharmaceuticals is selling for 285.86 as of the 14th of July 2024. This is a 1.54 percent decrease since the beginning of the trading day. The stock's lowest day price was 280.6. Madrigal Pharmaceuticals has only a 8 % chance of going through financial distress over the next few years but had a somewhat ok performance during the last 90 days. Equity ratings for Madrigal Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 14th of June 2024 and ending today, the 14th of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
6th of February 2007
Category
Healthcare
Classification
Health Care
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania. The company has 21.31 M outstanding shares of which 4.08 M shares are now shorted by private and institutional investors with about 6.95 trading days to cover. More on Madrigal Pharmaceuticals

Moving together with Madrigal Stock

  0.74VRAX Virax Biolabs GroupPairCorr

Moving against Madrigal Stock

  0.78VTYX Ventyx BiosciencesPairCorr
  0.67FENC Fennec PharmaceuticalsPairCorr
  0.61WAT WatersPairCorr
  0.59FLGC Flora Growth CorpPairCorr
  0.48HCM HUTCHMED DRCPairCorr
  0.38IKT Inhibikase TherapeuticsPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Madrigal Stock Highlights

ESG Sustainability
Environmental
Governance
Social
President CEOWilliam Sibold
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.00120.0013
Notably Down
Slightly volatile
Total Current Liabilities124.5 M118.5 M
Sufficiently Up
Slightly volatile
Total Assets672.6 M640.5 M
Sufficiently Up
Slightly volatile
Total Current Assets669.1 M637.3 M
Sufficiently Up
Slightly volatile
Debt Levels
Madrigal Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Madrigal Pharmaceuticals' financial leverage. It provides some insight into what part of Madrigal Pharmaceuticals' total assets is financed by creditors.
Liquidity
Madrigal Pharmaceuticals currently holds 117.19 M in liabilities with Debt to Equity (D/E) ratio of 0.6, which is about average as compared to similar companies. Madrigal Pharmaceuticals has a current ratio of 2.5, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Madrigal Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Depreciation

965,149
Madrigal Pharmaceuticals (MDGL) is traded on NASDAQ Exchange in USA. It is located in Four Tower Bridge, West Conshohocken, PA, United States, 19428 and employs 376 people. Madrigal Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.09 B. Madrigal Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 21.31 M outstanding shares of which 4.08 M shares are now shorted by private and institutional investors with about 6.95 trading days to cover. Madrigal Pharmaceuticals currently holds about 211.77 M in cash with (324.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.38.
Check Madrigal Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
Madrigal Pharmaceuticals maintains a total of 21.31 Million outstanding shares. The majority of Madrigal Pharmaceuticals outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Madrigal Pharmaceuticals to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Madrigal Pharmaceuticals. Please pay attention to any change in the institutional holdings of Madrigal Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Also note that almost three million one hundred ninety-six thousand seven hundred twenty-five invesors are currently shorting Madrigal Pharmaceuticals expressing very little confidence in its future performance.
Check Madrigal Ownership Details

Madrigal Stock Institutional Holders

InstituionRecorded OnShares
Rtw Investments, Llc2024-03-31
397 K
Geode Capital Management, Llc2024-03-31
346.9 K
Morgan Stanley - Brokerage Accounts2024-03-31
288.6 K
Rock Springs Capital Management Lp2024-03-31
285.9 K
Jane Street Group, Llc2023-12-31
216.8 K
Ra Capital Management, Llc2024-03-31
204.5 K
Bain Capital Life Sciences Investors, Llc2024-03-31
197 K
Pictet Asset Manangement Sa2024-03-31
184.2 K
Armistice Capital, Llc2024-03-31
168 K
Hhg Plc2024-03-31
2.6 M
Baker Bros Advisors Lp2024-03-31
M
View Madrigal Pharmaceuticals Diagnostics

Madrigal Pharmaceuticals Historical Income Statement

At this time, Madrigal Pharmaceuticals' Total Other Income Expense Net is quite stable compared to the past year. Selling General Administrative is expected to rise to about 113.6 M this year, although the value of EBIT is projected to rise to (361.5 M). View More Fundamentals

Madrigal Stock Against Markets

Madrigal Pharmaceuticals Corporate Management

Thomas HareSenior ManagementProfile
Remy SukhijaVP OfficerProfile
PharmD MBASenior AffairsProfile
Ronald FilippoChief OfficerProfile
Rebecca MDChief FounderProfile

Additional Information and Resources on Investing in Madrigal Stock

When determining whether Madrigal Pharmaceuticals is a strong investment it is important to analyze Madrigal Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Madrigal Pharmaceuticals' future performance. For an informed investment choice regarding Madrigal Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(23.13)
Return On Assets
(0.40)
Return On Equity
(0.89)
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.